In a lung cancer of the blood analyzer will improve the study of the tens of

 Perlong medical equipment nets , in the United States (university of
California San Francisco, (UCSF) scientists at the head of the international research
group in molecular genetics in lung cancer in the field of the largest two blood
analyzer clinical studies show that, molecular detection than traditional methods can
more accurately predict lung cancer early in the possibility of death, the results
will help improve the hundreds of thousands of patients each year the chances of
survival.
 Published in January 27, 2012 issue of The medical journal The Lancet (The
Lancet) of The study, reported The measure 14 genes in cancer tissue of The activity
of testing how to improve The accuracy of The prognostic, which can help guide to The
most common form of lung cancer--not The squamous non-small cell lung cancer of The
treatment of patients.
 The two independent clinical tests include a 433 cases of northern California
early analysis of patients with lung cancer tissue samples of the blind, and another
1006 cases of China early lung cancer research. The two clinical trials showed, the
detection can accurately predict lung cancer surgery in 5 years after the chance of
dying is low, medium or high.
 The university of California San Francisco, Helen's comprehensive cancer,
heart surgery in tumor famous professor and breast cancer plan leaders, medical doctor
Jablons said: "it is very exciting, a year, it might help hundreds of thousands of
people live longer." The study is from the Jablons professors and the university of
California San Francisco, associate professor of thoracic surgeons, a medical doctor
Mann common leadership finish.
 At present the doctor for lung cancer early evaluation depends on the size of
the tumor, location and the microscopic phenotype. Then these are called information
be used to guide the stage after the operation further treatment. If the doctor can
more accurately prognosis, is more likely to benefit from further treatment of
patients can immediately after surgery treatment, so as to avoid any remaining cancer
cell growth opportunities.
 Other research evidence, a lymph node metastases to the early lung cancer
chemotherapy can prevent recurrence. This lymph node metastases can increase the other
cannot be detected the transfer of risk.
 The scientists plan to design a large clinical trial to further validation
USES the algorithm can help guide treatment and lung cancer patients live longer.
 The research in China is part of the Chinese clinical trial group (CTCC) the
first major clinical trials. The Chinese clinical trial group (CTCC) is the Chinese
mainland companies and university hospital in breast cancer surgery UCSF under the
help of the leaders of the collaboration, aimed at higher risk of lung cancer in
China.
 Mann said the doctor: "the Chinese clinical test group represents Chinese and
western experts clinical study of a revolutionary new way of cooperation. The group
first important achievements of this will help lung cancer care molecular
individuality, and become a tumor biological basis in the first of interracial
research paradigm, the result can be used to try to improve the clinical effect of
most patients."
 Lung cancer prognostic difficulties
 Lung cancer is the two countries and global lead to cancer is the most common
cause of death. Lung cancer deaths each year than died of breast cancer, colon cancer
and prostate cancer people combined, took more than a year to lung cancer 150000
americans and about 1.4 million all over the world people's life. In the five years
after diagnosis, about 85% of americans will die from various types of lung cancer.
 Most lung cancer is caused by smoking, but there are other reasons, such as
contact asbestos, chemical products, environmental factors, and genetic
predisposition.
 One of the challenges for treating the disease is often cause in early will
not be discovered. Early stage usually have no symptoms, but it is the most effective
treatment for the stage. In the United States only about 30% of patients in the first
stage was diagnosed with lung cancer, leading to an overall survival rate is low.
 Jablons doctors say, even if in the earliest stages is lung cancer check out,
patient is to face serious mortality. Different from the early was found to have
obvious survival advantage and other types of cancer, about 35-45% of a period of
patients with lung cancer even the operation is a success, also can be in five years
because of recurrence and death. And the prognosis detection can solve cannot identify
the difficulty of these patients.
 Lung cancer treatment
 For local lymph nodes have spread of lung cancer, standard treatment is
operation and postoperative chemotherapy. For no local lymph node diffusion of
patients, treatment is often after surgery clinical observation. In "observation and
wait for" period, the doctor only in a cancer recurrence will recommend further
treatment-surgery, chemotherapy or radiation therapy.
 The doctor is the difficulty of the many early lung cancer is very small, the
notice of the cancer cells were hidden in the lungs, or the whole body, in the growth
of the matter after the surgery and forming tumors, and cause cancer recurrence.
Almost half of a period of patients with lung cancer has this very early metastatic
cancer.
 For the past two and three phase of patients with lung cancer research shows
that, in tumor recurrence can be detected before treatment as soon as possible to
improve the chance of survival.
 However, in view of the risk transfer (even if it is a period of the lung
cancer), the treatment guidelines also suggest consideration to be considered at high
risk of recurrence of patients with a period of chemotherapy.
 This study published in the lancet research data shows that the new molecule
detection can better recognition after surgery patients at high risk of early death,
so can be consider using a more effective early chemotherapy guide.
 Molecular testing how to predict the survival rates of patients with lung
cancer
 This molecule detection is the university of California San Francisco, was
originally developed technology as the foundation, based in Mountain View by a
California city (Mountain View) Pinpoint Genomics company developed the success. Its
technology platform using the is a known as quantitative polymerase chain reaction
(qPCR) standard laboratory technology.
 Analysis program from a piece of paraffin cancerous tissue samples of the
patients start.

                   Article : From perlong medical (http://www.pl999.net/)